This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Eltrombopag Taste Testing in Healthy Adult Volunteers

This study has been completed.
Information provided by (Responsible Party):
GlaxoSmithKline Identifier:
First received: June 15, 2007
Last updated: March 15, 2012
Last verified: February 2011
Based on a need for a pediatric formulation of eltrombopag for the treatment of pediatric thrombocytopenia, this study will help determine the best tasting pediatric formulation of eltrombopag. Healthy adult volunteers who are able to taste bitterness and who do not have a high sensitivity to bitterness will be enrolled. The subjects will evaluate different formulations and rate them based on the bitterness and effectiveness of sweetners. The outcome of this study will help support a decision for a new pediatric formulation of eltrombopag.

Condition Intervention Phase
Healthy Subjects Purpura, Thrombocytopenic, Idiopathic Drug: eltrombopag Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Single
Primary Purpose: Treatment
Official Title: Eltrombopag Pediatric Formulation Taste Testing in Healthy Adult Volunteers

Resource links provided by NLM:

Further study details as provided by GlaxoSmithKline:

Primary Outcome Measures:
  • To establish a taste preference of eltrombopag in a pediatric formulation taken at initial dosing, 3hours, and 6 hours on Day 1 & 2. [ Time Frame: at initial dosing, 3hours, and 6 hours on Day 1 & 2. ]

Secondary Outcome Measures:
  • Saftey will be monitored by: - vital signs and clinical labs will be taken at all visits [ Time Frame: all visits ]
  • - physical exam and an echocardiogram (ECG) will be done at Day 1 & 2 [ Time Frame: done at Day 1 & 2 ]

Enrollment: 12
Study Start Date: May 2007

Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • healthy adult based on a medical evaluation by a responsible physician
  • male or female adult between 18 and 55 years old
  • female subjects who are not pregnant or lactating
  • females who are unable to have children must have documented medical verification
  • females who are able to have children must have a negative pregnancy test
  • capable of giving written informed consent

Exclusion criteria:

  • subjects who are unable to taste bitterness or are extrememly sensitive to bitterness
  • participated in a clinical trial within 30 days
  • exposure to more than four new medicines within 12 months prior to the first day of dosing
  • history of sensitivity to any of the study medications
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00487968

United States, Kansas
GSK Investigational Site
Overland Park, Kansas, United States, 66211
Sponsors and Collaborators
Study Director: GSK Clinical Trials GlaxoSmithKline
  More Information

Responsible Party: GlaxoSmithKline Identifier: NCT00487968     History of Changes
Other Study ID Numbers: TRA110087
Study First Received: June 15, 2007
Last Updated: March 15, 2012

Keywords provided by GlaxoSmithKline:
healthy adult volunteers

Additional relevant MeSH terms:
Purpura, Thrombocytopenic
Purpura, Thrombocytopenic, Idiopathic
Blood Coagulation Disorders
Hematologic Diseases
Pathologic Processes
Skin Manifestations
Signs and Symptoms
Thrombotic Microangiopathies
Blood Platelet Disorders
Immune System Diseases
Hemorrhagic Disorders
Autoimmune Diseases processed this record on September 19, 2017